Pseudoephedrine/loratadine

Pseudoephedrine/loratadine
Pseudoephedrine/loratadine
Combination of
Pseudoephedrine Sympathomimetic
Loratadine H1 antagonist
Clinical data
Pregnancy cat. B(US)
Legal status OTC
Routes Oral
Identifiers
ATC code R01BA52
 YesY(what is this?)  (verify)

Pseudoephedrine/loratadine (trade names Claritin-D, Clarinase, Clarinase Repetabs) is an orally administered drug combination for the treatment of allergic rhinitis and the common cold. Pseudoephedrine, one of the naturally occurring alkaloids of ephedra, is a sympathomimetic used as a decongestant. It produces its decongestant effect facilitating vasoconstriction and shrinkage of congested mucosa in upper respiratory areas. Loratadine is a long acting H1 histamine antagonist that is less sedating than older substances of the type.

Contents

Indications and usage

Clarinase repetabs tablets are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation.

Composition

Clarinase Repetabs

A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.

Interactions, adverse effects and contraindications

Interactions, adverse effects and contraindications are described in more detail in the articles about pseudoephedrine and loratadine.

Interactions

When sympathomimetics are given to patients receiving monoamine oxidase inhibitors (MAO inhibitors), hypertensive reactions, including hypertensive crises may occur.

Adverse effects

During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of insomnia and dry mouth, both of which were commonly reported.

Contraindications

Clarinase is contraindicated in patients receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.

References

  • Drugs.com: Claritin-D
  • Israel Ministry of Health: Clarinase Repetabs
  • Haberfeld, H, ed (2009) (in German). Austria-Codex (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X. 

Wikimedia Foundation. 2010.

Поможем написать курсовую

Look at other dictionaries:

  • Pseudoephedrine — Systematic (IUPAC) name ( …   Wikipedia

  • Loratadine — Systematic (IUPAC) name …   Wikipedia

  • Phenylephrine — Systematic (IUPAC) name (R) 3 [ 1 hydroxy 2 (methylamino)eth …   Wikipedia

  • Ephedrine — Systematic (IUPAC) name (R*,S*) 2 (methylamino) 1 phenylpro …   Wikipedia

  • Norepinephrine releasing agent — Norepinephrine A norepinephrine releasing agent (NRA) is a type of drug which induces the release of norepinephrine and epinephrine from the pre synaptic neuron into the synapse. This in turn leads to increased extracellular concentrations of… …   Wikipedia

  • Cathine — Not to be confused with caffeine, a compound found in coffee and tea. Cathine Systematic ( …   Wikipedia

  • Phenylpropanolamine — Systematic (IUPAC) name 2 …   Wikipedia

  • Levonordefrin — Systematic (IUPAC) name 4 [(1R,2S) 2 amino 1 hydroxypropyl]benzene 1,2 diol Clinical data Pregnancy cat …   Wikipedia

  • Methoxamine — Not to be confused with methoxetamine. Methoxamine Systematic (IUPAC) name 2 amino 1 (2,5 dimethoxyphenyl)propan 1 ol Clinical data …   Wikipedia

  • Propylhexedrine — Systematic (IUPAC) name (RS) N,α dimethyl cyclohexylethylamine …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”